Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Amyris, Inc.

AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

Biomatter develops proteins and enzymes with Intelligent Architecture™ for health and sustainable manufacturing. The company provides solutions from initial concept to protein production.

Biomatter

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Amyris is a biotechnology company that manufactures sustainable ingredients using synthetic biology. Its technology involves converting basic plant sugars into bioidentical molecules for various applications.

Metric
Company Name	Amyris, Inc.	AMPLY Discovery	Biomatter	Ginkgo Bioworks Holdings, Inc.
Symbol	AMRS			DNA
MSH ID	COM:AMYRIS	COM:AMPLYDISCOVERY	COM:BIOMATTER	COM:GINKGOBIOWORKS
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Basic Materials	Healthcare & Health Services	Technology	Healthcare
Industry	Chemicals - Specialty	Biotechnology	Biotechnology	Biotechnology
Country	US	GB	LT	US
Stage				Grant
Employee Count	1.60K	7		1.22K
Website	amyris.com	amplydiscovery.com	biomatter.com	ginkgobioworks.com
LinkedIn			biomatter	ginkgo-bioworks
Founders

Metric
Market Cap	18.47M	725.64M
Enterprise Value
Monthly Web Traffic		20.69K
Web Traffic Growth		-0.17
Valuation
Raised Capital

Metric
Revenue	269.85M	251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	11.18M	142.64M
EBITDA	-514.21M	-600.68M
Operating Income	-592.66M	-672.23M
Net Income	-535.93M	-892.87M
EPS	-1.67	-0.46
Diluted EPS	-1.58	-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.01	0.75
Operating Profit Margin	-2.06	-3.34
EBITDA Margin	-1.91	-2.39
Net Profit Margin	-2.56	-3.55
Return on Equity	0.99	-0.65
Return on Assets	-0.76	-0.54
Return on Capital Employed	-2.00	-0.51

COM:AMYRIS

Amyris

Last Close

0.05

14/11 21:00

Market Cap

18.47M

Beta: -

Volume Today

46.75M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.03	-2.78
P/B Ratio	-0.03	1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.09	93.70
EV Multiple	2.39	-1.34

Metric
Days Sales Outstanding	125.86	73.17
Days Payables Outstanding	280.05	50.57
Days Inventory Outstanding	194.28	0.27
Operating Cycle	360.57	46.33
Cash Conversion Cycle	4.04	-7.39
Asset Turnover	0.30	0.15

Metric
Operating Cash Flow	-525.89M	-295.50M
Free Cash Flow	-631.84M	-336.30M
Cash Flow to Debt	-0.31	-0.63
Operating Cash Flow/Sales	-1.56	-1.14
Free Cash Flow Yield	-29.26	-0.16

Metric
Cash & Equivalents	64.44M	948.86M
Accounts Receivable	-9.58M	50.07M
Inventory	111.88M	46K
Goodwill	142.57M	49.24M
Debt to Capitalization	2.80	0.35
Debt to Assets	1.52	0.20
Current Ratio	0.52	6.78
Quick Ratio	0.22	5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.16	0.94
R&D to Revenue	0.41	2.05
SG&A to Revenue		1.32